Previous 10 | Next 10 |
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway dis...
2023-06-04 12:00:08 ET Billions of dollars in sales across various MedTech markets will be at stake if there is a broader acceptance of weight loss drugs developed by Novo Nordisk ( NVO ) and Eli Lilly ( NYSE: LLY ), Morgan Stanley argued in a research note last week. Novo N...
2023-06-01 05:16:01 ET Summary Baker Brothers' 13F portfolio value increased from $16.65B to $18.38B, with the largest five stakes in Seagen, Incyte, BeiGene, ACADIA Pharma, and Madrigal Pharma. The firm disposed of its stakes in Ascendis Pharma A/S and Horizon Therapeutics, while...
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway dise...
2023-05-08 08:53:22 ET Rhythm Pharmaceuticals ( NASDAQ: RYTM ) announced Monday that Health Canada approved its weight management agent Imcivree as a subcutaneous injection for patients aged six years and older with certain rare genetic diseases of obesity. Accordingly, Imcivr...
-- First and only approved therapy in Canada that targets genetic impairment in the MC4R pathway - a root cause of early-onset, severe obesity in these patients – -- Approval granted following a Priority Review by Health Canada – BOSTON, May 08, 2023 (GLOBE NEWSWIRE)...
2023-05-07 12:00:27 ET Patients in the U.S are expected to dish out $10B on obesity medicines in 2027, marking an $8.1B rise or over 378% growth for the period 2023 – 2027, the latest industry report on pharma spending from the drug analytics firm IQVIA Holdings ( IQV ) indicates...
2023-05-03 02:18:02 ET Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2023 Earnings Conference Call May 2, 2023 8:00 A.M. ET Company Participants David Connolly - Executive Director of Investor Relations and Corporate Communications David Meeker - Chairman, President, and Ch...
2023-05-02 07:15:41 ET Rhythm Pharmaceuticals press release ( NASDAQ: RYTM ): Q1 GAAP EPS of -$0.92 misses by $0.21 . Revenue of $11.5M (+671.8% Y/Y) misses by $0.62M . As of March 31, 2023, cash, cash equivalents and short-term investments were approximately $...
-- Strong U.S. commercial progress continues for IMCIVREE ® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA approval -- -- Launched IMCIVREE for BBS in Germany with federal reimbursement -- -- First patient...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...